Palla Pharma Ltd
ASX:PAL
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
AU |
Palla Pharma Ltd
ASX:PAL
|
47.8m AUD | 2.4 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
226.7B USD | 5 | ||
US |
Danaher Corp
NYSE:DHR
|
197.8B USD | 3.7 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45.3B USD | 7.3 | ||
CH |
Lonza Group AG
SIX:LONN
|
38.2B CHF | 4 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.8B USD | 6.8 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.5T KRW | 5.9 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.4B USD | -204.3 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.4B USD | 2.8 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25B USD | 9.3 | ||
US |
Waters Corp
NYSE:WAT
|
21B USD | 16.7 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.